Meet our Partnering Advisory Team
With larger partnering discussions now in view, we recently recruited our Partnership Advisory Team, comprised of executives with senior leadership experience in value creation and partnering in the pharmaceutical sector.
Chairman of Mallinckrodt and Revance Therapeutics; Former CEO of Shire plc
Angus served as CEO of Shire Plc for five years until his retirement in 2013 and was a member of its board of directors for thirteen years. Earlier in his career, Angus held roles of increasing responsibility at ICI, Zeneca, and AstraZeneca.
DBA (Honorary) Coventry University, UK
Angus led Shire through nine mergers and acquisitions, evolving the company into a global leader. Shire’s acquisitions during his tenure as CEO had a cumulative value exceeding $4 billion.
“I’m always up for advising a company that has the potential to deliver innovative treatments for patients!”
Expert, Licensing, M&A Transactions and Governance
As a biopharma executive and lawyer, Andrew structures deals to facilitate the development and commercialization of new drugs and therapies. He has negotiated and managed licensing and joint venture relationships for Baxter International and other companies on five continents.
JD Stanford Law School, USA
Andrew played an instrumental role in the sale of Medivation to Pfizer for $14 billion, the sale of InterMune to Roche for more than $8 billion, and the sale of ImClone to Eli Lilly for $6.5 billion.
“This is a company that’s addressing a problem that afflicts every human being.”
President & CEO, PDL BioPharma
Dominique has more than 35 years of leadership experience successfully commercializing a broad range of biotech and pharmaceutical products in the US and internationally. He served as Senior Vice President and Chief Marketing Officer of Alexion in 2014-2015.
MBA INSEAD, France
Dominique was responsible for relaunching the growth of Amgen’s Inflammation Business Unit in 2011-2013, including Enbrel, a leading treatment for rheumatoid arthritis with US revenues exceeding $4 billion.
“The control of inflammation is key to addressing a wide range of unmet medical needs.”
Expert, Pharmaceutical Product Development
In his most recent role, Rami headed the outreach and partnership efforts at Spectrum Therapeutics, a Canopy Growth Corporation subsidiary that focuses on cannabinoid therapeutics. He had previously led the company’s research and development effort, involving several clinical development programs and discovery initiatives addressing nervous system disorders (including pain) and cancer supportive care.
PhD Experimental Medicine McGill University, Canada
Rami and his teams have identified and evaluated hundreds of products and product candidates in clinical and preclinical development.
“Pain is a ‘screaming’ and multi-faceted medical need, and it’s central to successful disease management. I believe that Antibe’s research program is a path to better medicines for pain.”